Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: johnsto1 who wrote (6248)	4/30/2002 1:43:53 PM
From: johnsto1	Read Replies (1) \| Respond to of 52153

DJ MARKET TALK: Trail Recepter May Lead Human Genome Higher Edited by Thomas Granahan Of DOW JONES NEWSWIRES (Call Us: 201-938-5299; All Times Eastern) 1:37 (Dow Jones) Human Genome Sciences (HGSI) shares are gaining 5% after the company said it would start clinical trials on an anticancer drug, Trail Recepter-1, which Banc Of America analyst James Reddoch calls "a smart bomb." The drug finds cancer cells by recognizing a Trail Receptor-1 protein, binds to them, activates a "death receptor" and begins a programmed cell death. Reddoch says the drug has "blockbuster potential" but also two known obstacles: (1) the Trail pathway is unproven and (2) the drug is an activator whereas most are inhibitors, and activation is thought to be harder than inhibition. (GS)